The analysis was performed by pooling the efficacy of CT plus an anti-EGFR agent crossover to CT plus an anti-VEGF agent, versus CT plus an anti-VEGF agent crossover to CT plus anti-EGFR agent on the OS of patients with KRAS-WT who had different tumor localization. This evidence concerns the gene KRAS and neoplasm.